Celltrion’s Herzuma receives Europe nod

Celltrion’s Herzuma (trastuzumab) 150mg powder for concentrate for infusion is “now approved for marketing in the 28 member states of the European Union (EU)”, as well as Norway, Liechtenstein and Iceland, after the biosimilar of Genentech’s Herceptin treatment for forms of cancer was approved by the European Commission.